IPSEN (OTCMKTS:IPSEY) Sets New 1-Year High - What's Next?

Key Points

• IPSEN's shares reached a new 52-week high of $48.00 (last traded $48.00), rising about 4.1% from the prior close, though trading volume was light at 300 shares.
• Analyst sentiment is mixed — the consensus is an average "Hold" rating (one Buy, one Hold, one Sell), with Deutsche Bank reiterating a Buy and UBS downgrading the stock to Hold.
• Ipsen is a global biopharmaceutical company focused on oncology, neuroscience and rare diseases with key drugs like Cabometyx and Decapeptyl, and its 50-day ($43.74) and 200-day ($38.32) moving averages show a positive price trend.

IPSEN (OTCMKTS:IPSEY - Get Free Report)'s share price reached a new 52-week high on Wednesday . The company traded as high as $48.00 and last traded at $48.00, with a volume of 300 shares changing hands. The stock had previously closed at $46.30.

Wall Street Analysts Forecast Growth

IPSEY has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of IPSEN in a research report on Tuesday, February 17th. UBS Group downgraded IPSEN from a "strong-buy" rating to a "hold" rating in a research note on Thursday, January 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold".

IPSEN Stock Up 4.1%

The business has a 50 day moving average price of $43.74 and a two-hundred day moving average price of $38.32.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company's oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.